Amneal Pharmaceuticals Inc, a company engaged in the development, manufacture, and distribution of generic and specialty pharmaceutical products, has seen a notable insider transaction trend.

After hours: October 18 at 7:43 PM EDT Loading Chart for AMRX ...

Nasdaq-listed Amneal Pharmaceuticals, which already operates multiple manufacturing facilities in Gujarat, is further ...

Amneal Pharmaceuticals Inc (AMRX) reports a 17% revenue increase and raises 2024 guidance amid key product launches and strategic developments.

Amneal plans to launch five additional biosimilar products between 2025 and 2027. The company is focused on internal pipeline growth and strategic business development opportunities. Amneal aims to ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the ...

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Furthermore, Amneal is expanding internationally, expecting revenues of $50 million to $100 million by 2027, and plans to launch five additional biosimilar products between 2025 and 2027.

As part of the deal, Amneal will receive a license to market Metsera’s products in select emerging markets like India and certain Southeast Asian countries should Metsera’s drugs eventually ...